🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 10 of 757 · Phase 3 first, then by program name

  1. ASPRO 320 mg, comprimé, CALCIUM HYDROGEN PHOSPHATE DIHYDRATE, DICLOFENAC ARROW 1 %, gel en flacon pressurisé

    Tour Hekla

    Thrombotic episodes in superficial venous malformations in children

    phase 3 small molecule active

    1 trial

  2. ASSURE: An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)

    Gilead Sciences International Limited

    Primary Biliary Cholangitis

    phase 3 other active

    1 trial

  3. AT132

    Astellas Pharma GmbH

    X-linked Myotubular Myopathy (XLMTM)

    phase 3 small molecule active

    1 trial

  4. AT2221, ATB200

    Amicus Therapeutics Europe Limited

    Adult Subjects With Late Onset Pompe Disease (LOPD)

    phase 3 small molecule active

    1 trial

  5. ATENATIV 50 UI/mL, poudre et solvant pour solution pour perfusion, Atenativ 1000 I.E. - Pulver und Lösungsmittel zur Herstellung einer Injektions- oder Infusionslösung, Atenativ 1000 I.E. Pulver und Lösungsmittel zur Herstellung einer Infusionslösung, Atenativ 1000 UI/20 ml polvere e solvente per soluzione per infusione endovenosa, Atenativ 50 NE/ml por és oldószer oldatos infúzióhoz vagy injekcióhoz, ATENATIV 1000 U.I., polvo y disolvente para solución para perfusión

    Pharma Mar S.A.

    Congenital antithrombin deficiency

    phase 3 small molecule active

    1 trial

  6. ATLG

    China SXT Pharmaceuticals

    Hematopoietic Stem Cell Transplantation

    phase 3 small molecule active

    1 trial

  7. ATOMOXETINE , PAROXETINE , MIANSERIN , VORTIOXETINE , VENLAFAXINE , DESVENLAFAXINE , KETAMINE , CLOMIPRAMINE , DULOXETINE , DOSULEPIN , IMIPRAMINE , AMITRIPTYLINE , ESCITALOPRAM , NORTRIPTYLINE , MILNACIPRAN , SERTRALINE , ESKETAMINE , FLUVOXAMINE , REBOXETINE , FLUOXETINE , TRAZODONE , CITALOPRAM , BUPROPION , AGOMELATINE , MIRTAZAPINE , ESKETAMINE , TIANEPTINE

    Disc Medicine

    Major depressive disorder

    phase 3 small molecule active

    1 trial

  8. ATORVASTATIN, ROSUVASTATIN, ROSUVASTATIN, ROSUVASTATIN, ROSUVASTATIN, Placebo to KJX839 (Inclisiran), ATORVASTATIN, INCLISIRAN, ATORVASTATIN, ATORVASTATIN

    Novartis Ophthalmics Europe

    Acute coronary syndrome (ST-elevation myocardial infarction [STEMI] or non-ST-elevation myocardial infarction [NSTEMI]) of recent onset.

    phase 3 small molecule active

    1 trial

  9. AUBAGIO 14 mg film-coated tablets, COLESTYRAMINE , -, Matched Placebo to Test, Matched Placebo for Comparator Teriflunomide, Tolebrutinib, -

    Sanofi Pharma Bristol-Myers Squibb

    Nervous system diseases

    phase 3 small molecule active

    1 trial

  10. AUBAGIO 14 mg film-coated tablets, Frexalimab, AUBAGIO 14 mg film-coated tablets, AUBAGIO 14 mg film-coated tablets, COLESTYRAMINE , AUBAGIO 14 mg film-coated tablets, Matched placebo for comparator teriflunomide, AUBAGIO 14 mg film-coated tablets, Matched placebo for test product frexalimab

    Sanofi Pharma Bristol-Myers Squibb

    multiple sclerosis

    phase 3 small molecule active

    1 trial

  11. AVELUMAB, DOSTARLIMAB, ATEZOLIZUMAB, AVELUMAB, CEMIPLIMAB, DOSTARLIMAB, NIVOLUMAB, PEMBROLIZUMAB, NIVOLUMAB, DURVALUMAB, CEMIPLIMAB, ATEZOLIZUMAB, PEMBROLIZUMAB, DURVALUMAB

    Cancer Prevention Pharma (Ireland) Limited

    Only patients with oncologic locally advanced or metastatic tumour (lung cancer, renal cell cancer (except IMDC favorable-risk treated Tyrosine Kinase Inhibitor [TKI] / immunotherapy [IO] combination), head and neck cancer, urothelial carcinoma, triple negative breast cancer, Merkel cancer, melanoma, hepatocellular carcinoma, colorectal carcinoma with microsatellite instability [MSI], esophageal squamous cell carcinoma, endometrial carcinoma, or cervical cancer, gastric/gastro-esophageal junction/esophageal adenocarcinoma, basal cell carcinoma or squamous skin carcinoma) in partial or complete response (except for melanoma, only patients in partial response) after 6 months of standard IO treatment (monotherapy or previously in combination with other immunotherapy (ipilimumab) or chemotherapy or continuous combination with pemetrexed or bevacizumab or TKI).

    phase 3 small molecule active

    1 trial

  12. AVP-786 matching Placebo, AVP-786, AVP-786

    Otsuka Novel Products GmbH

    Agitation in Patients With Dementia of the Alzheimer's Type

    phase 3 small molecule active

    1 trial

  13. AVP-786 matching placebo, AVP-786

    Otsuka Novel Products GmbH

    Agitation in Patients With Dementia of the Alzheimer's Type

    phase 3 small molecule active

    1 trial

  14. AXS-02

    Axsome Therapeutics

    Osteoarthritis, Knee

    phase 3 small molecule active

    1 trial

  15. AXS-02 (oral zoledronate)

    Axsome Therapeutics

    Complex Regional Pain Syndrome

    phase 3 small molecule active

    1 trial

  16. AXS-05

    Axsome Therapeutics

    Treatment Resistant Major Depressive Disorder

    phase 3 small molecule completed

    1 trial

  17. AXS-05

    Axsome Therapeutics

    Agitation in Patients With Dementia of the Alzheimer's Type

    phase 3 small molecule completed

    3 trials

  18. AXS-05

    Axsome Therapeutics

    Depression

    phase 3 small molecule completed

    1 trial

  19. AXS-05 (dextromethorphan and bupropion) oral tablets

    Axsome Therapeutics

    Major Depressive Disorder

    phase 3 small molecule completed

    1 trial

  20. AXS-05 (dextromethorphan-bupropion)

    Axsome Therapeutics

    Agitation in Patients With Dementia of the Alzheimer's Type

    phase 3 small molecule completed

    2 trials

  21. AXS-07

    Axsome Therapeutics

    Migraine

    phase 3 small molecule completed

    1 trial

  22. AXS-07 (MoSEIC meloxicam and rizatriptan)

    Axsome Therapeutics

    Migraine

    phase 3 small molecule completed

    2 trials

  23. AXS-07 (meloxicam-rizatriptan)

    Axsome Therapeutics

    Migraine

    phase 3 small molecule completed

    1 trial

  24. AXS-12 (Reboxetine)

    Axsome Therapeutics

    Narcolepsy

    phase 3 small molecule completed

    3 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources